Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site

描述（由申请人提供）：梅奥诊所长期致力于通过nctg、ECOG、ACOSOG、ACRIN、RTOG和GOG支持和领导NCTN临床试验。梅奥诊所是NCCTG的创始机构和运营基地，直到它与CALGB和ACOSOG合并形成联盟。梅奥研究人员在这些组织以及新成立的组织（联盟、ECOG-ACRIN和NRG）中也扮演着领导角色。梅奥诊所癌症中心（MCCC）目前的临床研究结构继续优先考虑NIH赞助的试验，包括NCTN试验，而不是其他试验。MCCC内部有支持系统，以最大限度地增加收益，并支持这些试验的转化部分，包括生物标本收集和成像。梅奥的研究人员在试验领导方面也非常活跃。梅奥研究人员也非常有效地利用从NCTN试验中收集的数据和生物标本来解决重要和相关的研究问题。通过这种对研究的承诺，梅奥的研究人员在高影响力期刊上发表了多篇报告，并成功获得了包括R01基金在内的多项资助，以支持这项工作。

DESCRIPTION (provided by applicant): Mayo Clinic has had a long-standing commitment to support and lead NCTN clinical trials through NCCTG, ECOG, ACOSOG, ACRIN, RTOG, and GOG. Mayo Clinic served as the founding institution and operational base for NCCTG until its merger with CALGB and ACOSOG to form the Alliance. Mayo investigators have also had leadership roles in these groups as well as in the newly forming groups (Alliance, ECOG-ACRIN, and NRG). The current clinical research structure within the Mayo Clinic Cancer Center (MCCC) continues to prioritize NIH sponsored trial, including NCTN trials, over other trials. Support systems are in place within the MCCC to maximize accrual and to support the translational components of these trials, including biospecimen collection and imaging. Mayo investigators also remained very active in trial leadership. Mayo investigators have also been very effective in utilizing data and biospecimens collected from NCTN trials to address important and relevant research questions. Through this commitment to research, Mayo investigators have published multiple reports in high impact journals and successfully obtained multiple grants, including R01 grants, to support this work.